{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:26Z","timestamp":1777934186163,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T00:00:00Z","timestamp":1284595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>Treating two active malignancies concurrently can be exceedingly difficult. Complications can occur from the different treatment regimens, especially if they share common targets, and the progressing diseases can make managing treatment side-effects even more challenging. We report a case of a patient with coexisting CML and mRCC who progressed on multiple lines of mRCC therapy while experiencing significant dose limiting side-effects.<\/jats:p>","DOI":"10.1177\/1078155210382060","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T21:10:59Z","timestamp":1284671459000},"page":"436-439","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia \u2013 easier said than done? A case report"],"prefix":"10.1177","volume":"17","author":[{"given":"Fouad","family":"Al-Najjar","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Anthony","family":"Jarkowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,9,16]]},"reference":[{"key":"bibr1-1078155210382060","unstructured":"American Cancer Society. \u2018Cancer Facts and Figures 2009\u2019,\n                      Referencing,\n                      http:\/\/www.cancer.org\/Research\/CancerFactsFigures\/index (2009, accessed June 2010)."},{"key":"bibr2-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1159\/000258504"},{"key":"bibr3-1078155210382060","first-page":"42","volume":"22","author":"Yagoda A","year":"1995","journal-title":"Semin Oncol"},{"key":"bibr4-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32833123d4"},{"key":"bibr5-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"bibr6-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11520"},{"key":"bibr7-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"bibr8-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"bibr9-1078155210382060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V114.22.143.143","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood"},{"key":"bibr10-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"bibr11-1078155210382060","volume-title":"Sprycel\u00ae (dasatinib) package insert","author":"Sprycel\u00ae","year":"2009"},{"key":"bibr12-1078155210382060","volume-title":"Sutent\u00ae (sunitinib) package insert","author":"Sutent\u00ae","year":"2010"},{"key":"bibr13-1078155210382060","volume-title":"Nexavar\u00ae (sorafenib) package insert","author":"Nexavar\u00ae","year":"2009"},{"key":"bibr14-1078155210382060","volume-title":"Votrient\u00ae (pazopanib) package insert","author":"Votrient\u00ae","year":"2010"},{"key":"bibr15-1078155210382060","volume-title":"Afinitor\u00ae (everolimus) package insert","author":"Afinitor\u00ae","year":"2010"},{"key":"bibr16-1078155210382060","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.030"},{"key":"bibr17-1078155210382060","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i2.301"},{"key":"bibr18-1078155210382060","unstructured":"The National Cancer Institute. \u2018Common Terminology Criteria for Adverse Events (CTCAE) Version 4\u2019, Referencing, http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (2010, accessed June 2010)."},{"key":"bibr19-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"bibr20-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3033"},{"key":"bibr21-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000118413.92211.B6"},{"key":"bibr22-1078155210382060","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0780"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210382060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210382060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:03Z","timestamp":1777688043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155210382060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,16]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1177\/1078155210382060"],"URL":"https:\/\/doi.org\/10.1177\/1078155210382060","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,16]]}}}